The robotics technology provider, a spinoff from automotive manufacturer Chery, plans to float in a Shanghai offering that will also allow Midea to exit.

Gilead-backed AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

The Sompo, Relx and Fujitsu-backed big data analytics provider, valued at more than $20bn in 2015, has revealed it has confidentially filed for a public listing.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Novo, GSK and Amgen-backed NK oncology therapy developer Nkarta Therapeutics has set a range that will net it between $140m and $160m.

Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.

Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

Comcast, McKesson, Humana and Independence Health all scored exits as the health benefits services provider floated in an upscaled offering.